- Press Release
[📢 BRENUS Pharma unveils groundbreaking preclinical results for STC-10101 , a promising new drug candidate targeting Colorectal Cancer & Solid Tumors. #AACR23]
Menu
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens
